Association between CTC AR-V7 and overall survival in mCRPC. A total... | Download Scientific Diagram
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study | In Vivo
a) Progression free and b) overall survival probability of patients... | Download Scientific Diagram
Overall Survival (OS) for mCRPC patients treated with docetaxel for a... | Download Scientific Diagram
In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database - European Urology Focus
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate | Prostate Cancer and Prostatic Diseases
ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone
Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry | SpringerLink
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study | Journal of Nuclear Medicine
Overall Survival in mCRPC Cases Linked to Number of Radium-223 Doses - Renal and Urology News
Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors | Anticancer Research
Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience | Radiation Oncology | Full Text
Overall survival. mCRPC metastatic castration-resistant protate cancer.... | Download Scientific Diagram
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Understanding what matters to metastatic castration‐resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey - George - Cancer Medicine - Wiley Online Library
Clinical Parameters Predict Overall Survival in mCRPC | PracticeUpdate
Clinical Trial Results for JEVTANA® (cabazitaxel) Injection
Median overall survival (in months) for patients who did not receive... | Download Scientific Diagram
Overall survival and second primary malignancies in men with metastatic prostate cancer | PLOS ONE
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study - ScienceDirect
IJMS | Free Full-Text | The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone
ASCO GU 2022: Overall Survival after Progression on First Novel Hormonal Therapy in Patients with Metastatic Castration-Sensitive Versus Castration-Resistant Prostate Cancer (mCSPC Versus mCRPC)
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases
A-C) Overall survival of 68 patients with metastesis castration... | Download Scientific Diagram
ESMO Virtual Congress 2020: The Final Overall Survival Analysis of the PROfound Study: Olaparib vs Physician's Choice of Enzalutamide or Abiraterone in Patients with mCRPC and Homologous Recombination Repair Gene Alteration
